Harper Molly 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Dec 16, 2025
Insider Transaction Report
Form 4
Harper Molly
Director
Transactions
- Exercise/Conversion
Common stock, par value $0.001 per share
2025-12-12$5.78/sh+20,000$115,600→ 29,106 total - Sale
Common stock, par value $0.001 per share
2025-12-12$23.20/sh−15,527$360,195→ 13,579 total - Sale
Common stock, par value $0.001 per share
2025-12-12$23.73/sh−4,473$106,162→ 9,106 total - Sale
Common stock, par value $0.001 per share
2025-12-12$23.06/sh−6,746$155,563→ 2,360 total - Exercise/Conversion
Options to purchase common stock
2025-12-12−20,000→ 128,497 totalExercise: $5.78Exp: 2028-06-29→ Common Stock (20,000 underlying)
Footnotes (4)
- [F1]Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.
- [F2]Represents a weighted average price for the shares sold. Shares were sold in a range between $22.67 and $23.67 per share.
- [F3]Represents a weighted average price for the shares sold. Shares were sold in a range between $23.67 and $23.82 per share.
- [F4]Options vested in three annual tranches beginning on June 29, 2022.